Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • Finally FDA panel...

    Finally FDA panel confirms that Celecoxib is safe for heart

    Written by Medha Baranwal Baranwal Published On 2018-04-28T19:20:21+05:30  |  Updated On 28 April 2018 7:20 PM IST
    Finally FDA panel confirms that Celecoxib is safe for heart

    Cardiovascular (CV) safety of celecoxib, a prescription pain killer, is equivalent to that of naproxen and ibuprofen, concluded two panels of the U.S. Food and Drug Administration (FDA). The FDA's Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) voted 15 yes, 5 no, and 1 abstention in favor of the drug's safety. This was based on the Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen (PRECISION) trial.


    The drug celecoxib is sold by Pfizer under the brand name Celebrex. Its safety for heart was questionable for a long time. Now, with the voting of FDA, it is proven to pose no greater risk for causing heart attacks and strokes as compared to widely used pain relievers aproxen and ibuprofen. Based on the committee's conclusion, the FDA may change the advice about the drug's safety that it provides to doctors.


    PRECISION was a randomized, double-blind, active-controlled, parallel-group trial that began in 2006. It involved study on 24,081 patients who had osteoarthritis or rheumatoid arthritis and had or were at high risk for CV disease. It is a postmarketing trial requested by the FDA for evaluation of CV thrombotic risk of celecoxib following the emergence of new data about the risk for CV thromboembolic events linked with the cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs) rofecoxib and celecoxib.


    "I have been convinced by the committee that the trial did add value; I believe there is comparable CV event rate at the 100 mg dose, so my answer was 'yes' in that context," said temporary voting panel member Christianne L. Roumie, MD, MPH, associate professor, internal medicine and pediatrics, Institute for Medicine and Public Health, Vanderbilt University, Nashville, Tennessee.


    The study's primary Antiplatelet Trialists' Collaboration (APTC) endpoint was an independently assessed composite of CV death, nonfatal myocardial infarction, or nonfatal stroke. The trial's primary hypothesis was celecoxib's noninferiority to naproxen for the APTC endpoint. Other hypotheses were whether the drug was inferior to ibuprofen and whether ibuprofen was noninferior to naproxen for the APTC endpoint.





    Suzanne Robotti, the panel's consumer representative and the executive director of DES Action USA, a group advocating for people injured by diethylstilbestrol, was the lone abstainer. "I objected to the phrasing of the question," she said. "I found the results of [the study] to be reassuring but they didn't demonstrate safety; they [just] showed no increase in harm. A range of doses was not tested with Celebrex, and I'm not confident the medical community will restrain itself when prescribing in real life."


    For further related information click on the link: 10.1056/NEJMoa1611593




















    Cardiovascular SafetyCelebrexcelecoxibChristianne L. RoumieCOX-2CV safetyCV safety of celecoxibCV safety of pain killerdrug safetyFDAibuprofenmyocardial infarctionnaproxenNSAIDspain killerpain relieverspfizerPRECISION trialsafety of pain relieversSuzanne RobottiThrombosisU.S. Food and Drug Administration

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok